Objective Currently, there are no disease-modifying osteoarthritis drugs (DMOADs)
approved for osteoarthritis. It is hypothesized that a subtype of OA may be driven by …

Objective: To rescue chondrogenic differentiation of human mesenchymal stem cells
(hMSCs) in osteoarthritic conditions by inhibition of protein kinases. Methods: hMSCs were …

Objectives The main goal of this work was to analyse how treatment intervention with
tofacitinib prevents the early disturbances of bone structure and mechanics in the rat model …

Osteoarthritis (OA) is a multifactorial disease of the whole joint that has a complex
pathogenesis. There is currently no cure for OA. Tofacitinib is a broad JAK inhibitor that can …

Osteoarthritis (OA) is a major health problem worldwide that affects the joints and causes
severe disability. It is characterized by pain and low-grade inflammation. However, the exact …

Aim The aim of this work was to evaluate the effects of carnosol, a rosemary polyphenol, on
pro-inflammatory and catabolic mediators of cartilage breakdown in chondrocytes and via …

Osteoarthritis (OA) is the most common degenerative joint disease and no disease-
modifying therapy for OA is currently available. Targeting articular cartilage alone may not …

There is no disease-modifying therapy for osteoarthritis, a degenerative joint disease that is
projected to afflict more than 67 million individuals in the United States alone by 2030 …

Preserving of articular cartilage is an effective way to protect synovial joints from becoming
osteoarthritic (OA) joints. Understanding of the molecular basis of articular cartilage …

Recruitment of mesenchymal stem cells (MSCs) and aberrant bone formation, uncoupled
from resorption, is stimulated by an increase in subchondral bone concentration of …